Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Oncternal Therapeutics Inc
Healthcare
P/NCAV
0.88x
Ticker
ONCT
Exchange
NASDAQ
Country
United States
Close
8.77 $
Mkt Cap
25.8M $
EV
19.1M $
NCAV Burn Rate
50.7%
Current Ratio
6.94
Debt/Equity
0.0
EV/REV
24.3x
EV/EBIT
-0.5x
EV/FCF
-0.6x
Dilution
24.5% p.A
Total Net Income
-311.1M $
Cheapness
100.0%
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average